Send to

Choose Destination
Int J Cancer. 2019 Oct 14. doi: 10.1002/ijc.32733. [Epub ahead of print]

NO /RUNX3/Kynurenine Metabolic Signaling Enhances Disease Aggressiveness in Pancreatic Cancer.

Author information

Pancreatic Cancer Section, Laboratory of Human carcinogenesis, CCR, NCI, Bethesda, MD.
Breast and Prostate Section, Laboratory of Human carcinogenesis, CCR, NCI, Bethesda, MD.
Department of General, Visceral and Pediatric Surgery, University Medicine, Göttingen, Germany.
Cancer Genomic Section, Genetics Branch, CCR, NCI.
Institute of Pathology Univ. Hospital Heidelberg, Germany.
Pathology and Laboratory Medicine, Baltimore Veterans Affairs Medical Center, Baltimore, MD.
Regulatory RNA and Cancer Section, Genetics Branch, CR, NCI.
Ludwig Institute for Cancer Research, de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Division of Surgical Oncology, University of Maryland School of Medicine, Baltimore, MD.


Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is refractory to available treatments. Delineating the regulatory mechanisms of metabolic reprogramming, a key event in pancreatic cancer progression, may identify candidate targets with potential therapeutic significance. We hypothesized that inflammatory signaling pathways regulate metabolic adaptations in pancreatic cancer. Metabolic profiling of tumors from PDAC patients with a high- (>median, N=31) and low-NOS2 (inducible nitric oxide synthase) (<median, N=32) mRNA expression was performed. Differentially abundant metabolites were analyzed and linked with patient survival. The functional role of the prognostically significant metabolite and the mechanism of its regulation by NOS2/NO (nitric oxide)-mediated signaling pathway was elucidated. The level of kynurenine, a tryptophan metabolite, was associated with high NOS2 expression, and a higher level of kynurenine predicted poor survival in patients (N=63, P = 0.01). Gene expression analysis in PDAC tumors (N=63) showed a positive correlation between the expression of NOS2 and the tryptophan/kynurenine pathway genes, including indoleamine-2,3-dioxygenase 1 (IDO1) and several aryl hydrocarbon receptor (AHR)-target genes including NFE2L2 (NRF2), SERPINB2, IL1b, IL6 and IL8, which are implicated in pancreatic cancer. Consistently, treatment of pancreatic cancer cell lines with NO donor induced IDO1, kynurenine production, and the expression of AHR-target genes. Furthermore, kynurenine treatment enhanced spheroid growth and invasive potential of pancreatic cancer cell lines. Mechanistically, NO -induced IDO1/Kynurenine/AHR signaling was mediated by RUNX3 transcription factor. Our findings identified a novel NO /RUNX3/Kynurenine metabolic axis, which enhances disease aggressiveness in pancreatic cancer and may have potential translational significance in improving disease outcome. This article is protected by copyright. All rights reserved.


Pancreatic cancer; RUNX3; kynurenine; nitric oxide; prognosis; therapeutic targets


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center